Intelligent Photonics

Invuity’s patented Intelligent Photonics™ devices provide direct visualization of the surgical cavity enabling enhanced precision, efficiency and safety. Our technology is integrated into sophisticated retractor systems, handheld devices and intracavity drop-in illuminators; each utilizing our proprietary waveguide technology that directs and shapes light into broad, uniform illumination to provide enhanced direct visualization inside dark surgical cavities. In addition, it converts traditional thermally hot, concentrated light output to thermally cool volumetric illumination throughout the entire surgical cavity.

Find out more about our technology

waveguide-home

Transforming Minimal access Surgeries Through Advanced Visualization

Invuity is committed to leveraging advanced photonics technology to transform and create a new standard of care for minimal access surgery.

precision-efficiency-safety

Invuity® Announces PhotonBlade™ Dynamic Precision Illuminator With Enhanced Energy

Offers exceptional visualization within the surgical cavity, for precision and safety LAS VEGAS, April 27, 2017 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), an advanced surgical illumination company focused on minimal access surgery, today at the 18th American Society of Breast Surgeons annual scientific conference, announced the introduction of PhotonBlade™, a dynamic precision illuminator with enhanced energy delivery. PhotonBlade represents an entirely new category of Intelligent Photonics®, delivering directed, thermally cool illumination at the precise point of surgical treatment. Further, PhotonBlade’s novel energy platform consists of a proprietary shielded blade for precise ...

Read More

Invuity Reports 2017 First Quarter Results

Achieves revenue growth of 41% and gross margin expansion over prior year quarter SAN FRANCISCO, April 26, 2017 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today reported financial results for the three months ended March 31, 2017. Q1 2017 Highlights Revenue grew 41% to $9.0 million compared to revenue of $6.4 million in the 2016 first quarter. Gross margin of 76.7% improved significantly from gross margin of 67.1% in the 2016 first quarter. Approximately 770 hospitals purchased Invuity devices in the first quarter of 2017, up from 555 hospitals in the first quarter of 2016. Approximately 269,000 ...

Read More

Invuity Announces 2017 First Quarter Financial Results and Conference Call Date

SAN FRANCISCO, April 12, 2017 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a leading surgical photonics company, today announced that it will release its 2017 first quarter financial results after the market closes on Wednesday, April 26, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Wednesday, April 26, 2017, to discuss the financial results and other business developments. Interested parties may access the live call via telephone by dialing 1-877-556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 5223865. To listen to the live call via Invuity's websit...

Read More
icon-surgeon

Surgeons

Read More

icon-hospital

Hospitals & Surgery Centers

Read More

icon-patient

Patients

Read More

Testimonials

“The light improves my visualization in the surgical field, allowing me to be more precise with my bone cuts and joint preparation”

Selene Parekh, MD
North Carolina Orthopaedic Clinic
Durham, NC

“The illumination of the operative field creating improved operative efficiency (with no longer needing to wear my headlight) along with added patient safety have made the Eikon Illuminated Retractor System the tool of choice in my skin sparing and nipple sparing mastectomies.”

Richard E. Fine, MD
The West Clinic Comprehensive Breast Center
Memphis, TN

“The Saber Waveguide with Yankauer is one of the most significant technological advancements in orthopedic surgery this year.  I’m excited to begin using it in my total hip replacement, oncology and orthopedic trauma surgeries.”

Herrick J. Siegel, MD
Professor of Surgery and Head of Orthopaedic Oncology
UAB Medical Center
Birmingham, AL